Myelin oligodendrocyte glycoprotein transduced T cell therapy - ImCyse

Drug Profile

Myelin oligodendrocyte glycoprotein transduced T cell therapy - ImCyse

Alternative Names: MOG autologous T-lymphocyte cell therapy - ImCyse; MOG cytolytic CD4+ T-cell therapy - ImCyse; MOG gene therapy - ImCyse; MOG peptide gene therapy - ImCyse; MOG transduced T-cells - ImCyse; MOG-autologous CD4+ cell therapy - ImCyse; Myelin oligodendrocyte glycoprotein gene therapy - ImCyse; Myelin oligodendrocyte glycoprotein transduced T-cells - ImCyse

Latest Information Update: 22 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ImCyse
  • Developer GlaxoSmithKline; ImCyse; Rega Institute for Medical Research; Trinity College Dublin
  • Class Anti-inflammatories; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunosuppressants; Myelin-oligodendrocyte glycoprotein expression stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Type 1 diabetes mellitus
  • Preclinical Multiple sclerosis
  • Research Cancer; Infections; Myasthenia gravis; Rheumatoid arthritis
  • Discontinued Asthma; Graft-versus-host disease

Most Recent Events

  • 22 Aug 2017 Discontinued - Preclinical for Asthma in Belgium (unspecified route)
  • 22 Aug 2017 Discontinued - Preclinical for Graft-versus-host disease in Belgium (unspecified route)
  • 22 Aug 2017 Early research in Infections in Belgium (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top